Mfsd2a‐Targeted Therapy for Ischemic Stroke: Mechanisms, Evidence, and Future Prospects

Background Ischemic stroke remains a major cause of global disability and mortality, with blood–brain barrier (BBB) dysfunction being a pivotal event in its pathology. Major facilitator superfamily domain‐containing 2a (Mfsd2a), a key lipid transporter at the BBB, has emerged as a promising yet underexplored therapeutic target. Objective This review proposes a unifying framework that positions Mfsd2a as a central indicator of ischemic stroke pathophysiology and a potential target for treatment. Although direct clinical evidence remains in its early stages, this review synthesizes foundational knowledge from diverse fields. Methods We revisit the established biological functions of Mfsd2a, including its role in inhibiting caveolae‐mediated transcytosis and transporting omega‐3 fatty acids, and detail its core mechanisms in maintaining BBB integrity. This review also correlates these functions with their significant downregulation following ischemic stroke. We then critically evaluate the limited but compelling preclinical evidence from models in which Mfsd2a has been directly targeted and explore innovative therapeutic strategies. Finally, we explicitly address the current limitations, including the scarcity of direct intervention studies, and outline a translational roadmap for future research. Results By integrating this dispersed evidence chain, this review aims to solidify the theoretical foundation for Mfsd2a‐targeted therapies and accelerate their clinical development. Conclusion Targeting Mfsd2a shows a promising therapeutic strategy to protect the BBB and improve neurological outcomes after ischemic stroke.